Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ASH18

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Clock ticking on biosimilar Enbrel in US

10-month review for drug

- PMLiVE

Amgen’s Kyprolis and Blincyto on track for European approval

Double CHMP recommendation backs the myeloma and leukaemia drugs

- PMLiVE

Amgen and Allergan close on Avastin biosimilar filing

ABP 215 matches reference drug in study

- PMLiVE

Amgen granted priority review for extended use of Kyprolis

Trial data shows myeloma drug's improvement over Velcade

- PMLiVE

Amgen boosts pipeline with two deals topping $3bn

AcquiresDezima Pharma and signs collaboration with Xencor

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

Novartis launches first biosimilar Zarxio in the US

Follows Amgen's failure to block Neupogen-version from release

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links